Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | Microarray, qPCR, Western blot, RNAi etc. |
| Sample | gastric cancer tissues, cell lines (MGC-803, AGS, SGC-7901, BGC-823 and GES-1) |
| Expression Pattern | up-regulated |
| Function Description | LINC00152 was proven to have a higher expression level in GC tissues than in the adjacent normal tissues.GC cells proliferation was inhibited after LINC00152 was down-regulated.LINC00152 inhibited the expression of miR-193a-3p,which negatively regulated MCL1 In addition,GC cells proliferation was inhibited by cell transfection with shRNA-MCL1,and enhanced by transfection with miR-193a-3p mimics. Our study suggested that LINC00152 was overexpressed in GC tissues,and it down-regulated miR-193a-3p to enhance miR-193a-3p expression thereby promoting GC cells proliferation.Furthermore,an interesting discovery is that LINC00152 works as a competing endogenous RNA (ceRNA) through sponging miR-193a-3p and shares the identical responsive elements of miR-193a-3p with some signaling pathway factor like erb-b2 receptor tyrosine kinase 4 (ERBB4). |
| Pubmed ID | 29339419 |
| Year | 2018 |
| Title | LINC00152 down-regulated miR-193a-3p to enhance MCL1 expression and promote gastric cancer cells proliferation. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |